Vanta Bioscience Quarterly Results for Trading Insights

In Mar 2023, Vanta Bioscience (VANTABIO) reported revenue ₹1 Cr and net profit ₹-1 Cr — revenue -80.0% YoY. For annual financials, live price and key ratios, visit VANTABIO company profile.

Latest Quarter Net Profit
₹-1 Cr
QMar 2023
Quarterly Results

VANTABIO Quarterly Results — Revenue, Profit & EPS Highlights

Vanta Bioscience latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with VANTABIO fundamental valuation to assess whether the stock is under or overvalued.

  • Revenue of ₹1 Cr in Mar 2023 (-80.0% vs Mar 2022, -80.0% vs Mar 2022)
  • Net Profit of ₹-1 Cr in Mar 2023
  • EBITDA of ₹-1 Cr in Mar 2023 (-150.0% vs Mar 2022)
  • Operating Margin of -206.0% in Mar 2023 (-252.0pp vs Mar 2022)

Vanta Bioscience Quarterly Results — Revenue, EBITDA, Net Profit & EPS

VANTABIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2023 Mar 2022 Dec 2022 Dec 2021 QoQ YoY
Revenue (₹ Cr) 1 5 3 0 -80.0% -80.0%
Net Profit (₹ Cr) -1 0 -3 0 - -
EBITDA (₹ Cr) -1 2 -1 0 - -
EPS (₹) 0.00 0.11 -4.06 0.00 - -
Operating Margin (%) -206.0% 46.0% -20.0% 0.0% - -

VANTABIO Share Price Trend — 1-Year Movement Across Quarterly Results

Vanta Bioscience 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse VANTABIO institutional holdings to track promoter, FII and institutional holdings.

Profitability Ratios

Profit Margin -100.0%
EBITDA Margin -100.0%
Operating Margin -206.0%
ROE (Annual) -100.0%

Balance Sheet Highlights

Total Assets ₹86 Cr
Total Equity ₹4 Cr
Current Assets ₹15 Cr
Current Liabilities ₹56 Cr

Cash Flow Analysis

Operating Cash Flow ₹-2 Cr
Investing Cash Flow ₹-7 Cr
Financing Cash Flow ₹9 Cr
Net Cash Flow ₹0 Cr

Revenue Trend (₹ Cr)

Dec 2021 0
Dec 2022 3
Mar 2022 5
Mar 2023 1

Net Profit Trend (₹ Cr)

Dec 2021 0
Dec 2022 -3
Mar 2022 0
Mar 2023 -1

Operating Margin Trend (%)

Dec 2021 0.0%
Dec 2022 -20.0%
Mar 2022 46.0%
Mar 2023 -206.0%

VANTABIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Vanta Bioscience latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2025 		₹396,418.12 Cr 1652.2 14,875 3,125 +10.8% - 21.0% 127.1
Divis Laboratories
Sept 2025 		₹162,373.86 Cr 6070.0 2,860 689 +7.1% - 24.1% 233.7
Torrent Pharmaceuti…
Sept 2025 		₹140,630.85 Cr 4181.0 3,219 591 +11.3% - 18.4% 238.4
Lupin
Sept 2025 		₹106,664.75 Cr 2315.1 6,921 1,485 +23.2% - 21.5% 71.5
Dr Reddys Laborator…
Sept 2025 		₹102,844.71 Cr 1235.9 9,135 1,337 +1.1% - 14.6% 76.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores